SEP 11, 2018 09:42 PM PDT

Widely-Used Drug Contributed To Skin Cancer

WRITTEN BY: Nouran Amin

Credit:  MIT

In a research study at the University of Dundee, Queen Mary University of London and the Wellcome Sanger Institute, a drug, by the name of azathioprine, which is used to treat inflammatory bowel disease (IBD), arthritis and vasculitis as well as preventing organ rejection in transplant patients, has been identified as a contributor the development of skin cancer.

Published in Nature Communications, the research identified a `strong case for an association' between azathioprine and a mutation found in a common form of skin cancer known as cutaneous squamous cell carcinoma (cSCC). Previously, it was known that azathioprine leads to a heightened photosensitivity to UVA light. Such sensitivity is believed to be the key behind its contribution to skin cancers. The study found that the use of azathioprine leaves a ‘molecular fingerprint’ in skin cancers, implicating it in cSCC. "We recommend all physicians give appropriate advice on UVA avoidance including year-round sun protection for their patients on azathioprine,” explains Professor of Dermatology--Charlotte Proby in the School of Medicine at Dundee.

Credit: Ctdermgroup.com

However, the research team is not necessarily promoting the withdrawal of azathioprine. "As with all medications the risks must be balanced against the benefits, particularly with the need to treat potentially life-threatening diseases with an effective drug," explains Proby. “It is important that sun protection, skin surveillance and early diagnosis/lesion removal are part of the routine management of patients on azathioprine."

cSCC is a commonly diagnosed skin cancer. "It's important to protect your skin from the sun when it's strong, especially if you burn easily or are taking medications which make you more sun-sensitive. The most effective protection is to spend time in the shade and cover up with a hat, long-sleeved top, and sunglasses. For the bits you can't cover, use sunscreen with at least 4 stars and SPF 15 or higher for protection against both UVA and UVB rays,” says Sarah Lowes of Cancer Research UK.

The research also revealed the molecular nature of cSCC which highlighted the potential targets that may be developed for future treatments.

Source: University of Dundee, Nature Communications

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 16, 2019
Health & Medicine
SEP 16, 2019
Formation of Habitual Cannabis Use Drives Addiction
According to a new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier, shifting from brain systems controlling...
SEP 16, 2019
Microbiology
SEP 16, 2019
Vulnerability in Famously Hard-to-Target Viruses is Identified
The cold virus is famously difficult to target with drugs because it can mutate rapidly....
SEP 16, 2019
Drug Discovery
SEP 16, 2019
Experimental Drug Encourages Bone Growth in Children with Dwarfism
An experimental drug called vosoritide, alters certain proteins that block bone growth, which allowed the average annual growth of bone in a study of 35 ch...
SEP 16, 2019
Drug Discovery
SEP 16, 2019
Controlling The Release of Drug Components Using Artificial DNA
Studies carried out at the Technical University of Munich (TUM) can allow nanapoarticles to be released in pre-defined sequence at specified times. Using a...
SEP 16, 2019
Drug Discovery
SEP 16, 2019
Compound Found in Wine May Treat Anxiety
A study published in the journal Neuropharmacology claims that a compound found in red wine could be used as therapeutic for treating anxiety and depressio...
SEP 16, 2019
Drug Discovery
SEP 16, 2019
Can Psychedelics Treat Alcoholism?
Some of the first research on psychedelics in clinical settings was to assess their efficacy in treating alcoholism. In fact, LSD-based treatments for the ...
Loading Comments...